ProfileGDS5678 / 1424867_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 71% 69% 70% 67% 69% 72% 72% 70% 69% 69% 69% 67% 70% 72% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.4278871
GSM967853U87-EV human glioblastoma xenograft - Control 24.2847569
GSM967854U87-EV human glioblastoma xenograft - Control 34.3587970
GSM967855U87-EV human glioblastoma xenograft - Control 44.0593567
GSM967856U87-EV human glioblastoma xenograft - Control 54.2129469
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.549672
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.5256272
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.387670
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.2535369
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.2369769
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.2531269
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.1136367
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.3739970
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.5163872